1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Eckert & Ziegler SE

Eckert & Ziegler SE

0NZY.IL
Eckert & Ziegler SEGB flagInternational Order Book
13.39
EUR
-0.36
- -
837.90MMarket Cap
Eckert & Ziegler SE
0NZY.IL
(International Order Book)

Recent

price

13.39

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.89
0.92
0.95
0.92
1
1.1
0.94
1.09
2.72
1.45
1.43
1.45
1.78
1.97
2.37
4.99
5.06
Revenue per Share
0.08
0.08
0.08
0.07
0.05
0.08
0.08
0.12
0.26
0.18
0.17
0.28
0.24
0.21
0.27
0.78
0.79
Basic EPS, GAAP
0.07
0.01
0.05
0.04
0.02
0.1
0.11
0.18
0.24
0.27
0.23
0.04
0.06
0.17
0.39
0.52
0.48
Free Cash Flow per Basic Share
0.02
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.07
0.05
0.07
0.08
0.08
0.08
0.01
0.17
- -
Dividend per Share
1.09
1.19
1.27
1.32
1.4
1.57
1.66
1.77
2.02
2.22
2.35
3.01
3.4
3.56
3.57
4.02
4.29
Book Value per Share
0.43
0.48
0.55
0.49
0.52
0.72
0.82
0.96
1.15
1.4
1.72
2.02
1.84
2.78
2.78
3.29
3.54
Tangible Book Value per Share
125
127
127
127
127
127
127
127
62
123
124
124
125
125
125
63
63
Basic Weighted Avg Shares
111
116
120
117
127
140
120
139
169
178
176
180
222
246
296
312
317
Sales/Revenue/Turnover
16.49
19.56
16.53
10.98
9.65
12.67
12.84
12.54
12.85
19.29
19.93
18.97
20.66
18.93
22.72
24.13
23.84
Operating Margin (%)
10
8
8
9
7
9
9
9
9
11
11
10
11
13
19
17
18
Depreciation Expense
10
10
10
9
7
11
10
15
16
22
21
35
29
26
33
49
49
Net Income, GAAP
27.44
43.57
32.62
14.86
44.92
33.21
32.24
30.68
26.2
28.06
30.93
25.29
30.72
27.95
29.97
32.34
32.16
Effective Tax Rate (%)
9.38
8.97
8.58
7.71
5.32
7.67
7.97
10.6
9.56
12.34
12.09
19.14
13.17
10.69
11.25
15.63
15.61
Profit Margin (%)
-29
-29
-34
-32
-43
-39
-34
-34
-34
-44
-49
-60
118
-84
-72
-72
181
Working Capital
16
13
10
18
7
5
4
- -
- -
17
18
17
47
47
46
35
34
LT Debt
74
81
87
90
94
105
110
118
124
138
146
193
214
224
225
253
270
Total Equity
12.52
12.75
13.15
10.11
5.92
9.99
8.49
9.71
12.64
17.01
14.44
12.81
12.92
12.21
16.56
17.25
16.42
Return on Invested Capital (%)
12.59
11.13
10.63
8.02
7.03
10.31
8.35
12.36
13.06
15.84
13.47
18.27
12.45
10.56
12.5
17.74
17.47
Return on Capital (%)
14.45
14.52
13.2
11
7.87
11.39
9.32
13.52
13.73
16.96
15.08
20.76
14.66
12.11
14.93
20.52
19.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9
10
10
LT Borrowings
9
7
6
LT Finance Leases
28
28
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
63
63
Market Capitalization
1,112
956
908

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
245
248
255
Cash, Cash Equivalents & STI
121
129
124
Accounts Receivable, Net
50
45
52
Inventories
47
46
48
Total Current Liabilities
84
72
75
Payables & Accruals
- -
- -
- -
ST Debt
9
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.52%
12.09%
12.53%
Free Cash Flow
39.83%
50.87%
-34.41%
Net Income, GAAP
19.58%
21.98%
46.54%
Sales/Revenue/Turnover
8.96%
12.4%
5.45%
Total Cash Common Dividend
- -
165.78%
900.77%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
78
70
80
296
2025
68
81
75
88
312
2026
73
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.09
- -
0.27
2025
0.16
0.19
0.14
- -
0.78
2026
0.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.17
2026
- -
- -
- -
- -
- -
Similar Companies
T&R Biofab Co., Ltd. (246710.KQ)
IDenta Corp. (IDTA)
Alcon Inc. (ALC)
Eckert & Ziegler SE (EUZ.DE)
Ormand Industries Inc (OMDD)
Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
Business
Eckert & Ziegler SE is a Germany-based specialized radiopharmaceutical company that develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceutical products for the medical and research sectors, with a focus on oncology, cardiology, neuroscience, and molecular imaging applications. The company operates through production facilities and sales offices across Europe, the United States, and other regions, delivering a broad portfolio of products and services to hospitals, clinics, and research institutions. Main products and services: - Diagnostic radiopharmaceuticals for positron emission tomography and single-photon emission computed tomography imaging; includes established radiotracers and in-house development programs; provides kits, ready-to-use formulations, and custom labeling services - Therapeutic radiopharmaceuticals for targeted internal radiation therapy; includes beta- and alpha-emitting compounds, radiopharmaceuticals, and related dosimetry and patient-specific treatment planning support - Radiopharmaceutical manufacturing and contract development services; including GMP production of radioisotopes, radiopharmacy manufacturing, quality control testing, regulatory support, and batch release services - Research and development services; early-stage program support, radiochemistry expertise, preclinical and translational research collaboration, and credentialed access to radiopharmaceuticals for clinical trials - Imaging services and clinical support; radiopharmacology consulting, imaging protocol design, and patient management guidance for diagnostic and therapeutic procedures - Aftermarket and technical support; spare parts, maintenance, service contracts, calibration, and compliance assistance Latest major company changes: - Strategic partnerships and collaborations with pharmaceutical and academic partners to broaden radiopharmaceutical portfolio and accelerate late-stage development - Acquisitions or stake acquisitions that expand manufacturing capacity, geographic reach, or pipeline assets - Launch of new radiopharmaceutical products or expanded indications for existing products - Organizational restructuring or rebranding efforts to optimize global operations and regionalgo-to-market strategies - Expansion of production facilities or modernization of GMP-compliant manufacturing lines to meet rising demand - Reorganization of subsidiary entities to streamline corporate structure and align with strategic priorities Additional context: - Industry: Radiopharmaceuticals, diagnostic and therapeutic nuclear medicine - Segments: Manufacturing and sale of radiopharmaceuticals; clinical support services; contract development and manufacturing - Target markets: Hospitals, clinics, university medical centers, research institutions, and contract research organizations - Geographic operations: Europe (Germany headquarters and key facilities), North America, and other international markets - Founding year: 1997 - Headquarters: Berlin, Germany - Subsidiaries/parent: Operates as Eckert & Ziegler SE with several regional subsidiaries and distribution partners; belongs to a corporate group focused on radiopharmaceuticals and nuclear medicine research and applications